Document is current

Article History

Received: 26 July 2019

Accepted: 7 November 2019

First Online: 19 November 2019

Compliance with ethical standards

:

: N Yamamoto: Advisory board: Eisai, Takeda, OncoTherapy Science, Otsuka, Boehringer Ingelheim, Cimic; Corporate sponsored research: Quintiles, Astellas, Chugai, Eisai, Taiho, BMS, Pfizer, Novartis, Daiichi-Sankyo, Bayer, Boehringer Ingelheim, Kyowa-Hakko Kirin, Takeda, ONO. T. Shimizu: Corporate sponsored research: Bristol-Myers Squibb. Advisory board: Bristol-Myers Squibb, Takeda, The Consortium on Harmonization of Institutional Requirements for Clinical Research (CHAIR), Hong Kong, HKSAR; Corporate-sponsored Research: Chugai, Incyte Corporation, MSD, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, Novartis, Eisai, Millenium-Takeda, PharmaMar, FivePrime, 3D-Medicine, Symbio Pharmaceuticals, Chordia Therapeutics. Y. Fujiwara: Advisory board: Astra Zeneca, Bristol-Myers Squibb, MSD, ONO; Corporate sponsored research: Abbvie, Astra Zeneca, Bristol-Myers Squibb, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Incyte, Merck Serono, MSD, Novartis; Speaker bureau; Astra Zeneca, Bristol-Myers Squibb, Chugai, MSD, Novartis, ONO, Sysmex, Taiho. S. Iwasa: Corporate sponsored research: Bristol-Myers Squibb, Chugai. S. Kitano: Advisory board: Bristol-Myers Squibb, MSD. All the other authors have declared no conflicts of interest.

: All the procedures performed in studies involving human participants were conducted in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

: Informed consent was obtained from all individual participants for enrolment in clinical trials. For this type of study, additional formal consent is not required.